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TRBACKGROUND & AIMS: The b-catenin signaling pathway is
one of the most commonly deregulated pathways in cancer
cells. Amino acid substitutions within armadillo repeats 5 and 6
(K335, W383, and N387) of b-catenin are found in several tu-
mor types, including liver tumors. We investigated the mech-
anisms by which these substitutions increase signaling and the
effects on liver carcinogenesis in mice. METHODS: Plasmids
encoding tagged full-length b-catenin (CTNNB1) or b-catenin
with the K335I or N387K substitutions, along with MET,
were injected into tails of FVB/N mice. Tumor growth was
monitored, and livers were collected and analyzed by his-
tology, immunohistochemistry, and quantitative reverse-
transcription polymerase chain reaction. Tagged full-length
and mutant forms of b-catenin were expressed in HEK293,
HCT116, and SNU449 cells, which were analyzed by immu-
noblots and immunoprecipitation. A panel of b-catenin var-
iants and cell lines with knock-in mutations were analyzed
for differences in N-terminal phosphorylation, half-life, and
association with other proteins in the signaling pathway.RESULTS: Mice injected with plasmids encoding K335I or
N387K b-catenin and MET developed larger, more advanced
tumors than mice injected with plasmids encoding WT
b-catenin and MET. K335I and N387K b-catenin bound APC
with lower affinity than WT b-catenin but still interacted
with scaffold protein AXIN1 and in the nucleus with TCF7L2.
This interaction resulted in increased transcription of genes
regulated by b-catenin. Studies of protein structures sup-
ported the observed changes in relative binding affinities.
CONCLUSION: Expression of b-catenin with mutations in
armadillo repeats 5 and 6, along with MET, promotes for-
mation of liver tumors in mice. In contrast to N-terminal
mutations in b-catenin that directly impair its phosphoryla-
tion by GSK3 or binding to BTRC, the K335I or N387K sub-
stitutions increase signaling via reduced binding to APC.
However, these mutant forms of b-catenin still interact with
the TCF family of transcription factors in the nucleus. These
findings show how these amino acid substitutions increase
b-catenin signaling in cancer cells.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
The b-catenin signaling pathway is one of the most
commonly deregulated pathways in cancer. Amino-acid
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he b-catenin signaling pathway is one of the most
1 alterations within armadillo repeats 5 and 6 are found in
several tumor types, including liver tumors.
NEW FINDINGS
Expression of mutant forms of b-catenin found in several
cancer types, along with MET, promoted formation of liver
tumors in mice. The K335I or N387K substitutions
increased signaling via reduced binding to APC, but
these mutant forms of b-catenin still bound AXIN1 and
the transcription factor TCF7L2 in the nucleus.
LIMITATIONS
These studies were performed in cell lines and mice.
IMPACT
These findings reveal how these amino acid substitutions
in b-catenin increase signaling in cancer cells, including
those of the liver in which they are most commonly
observed.
Abbreviations used in this paper: AAR, amino acid repeat; APC, adeno-
matous polyposis coli; AXIN1/2, axis inhibition protein 1/2; CK1a, casein
kinase 1a; COSMIC, Catalogue of Somatic Mutations in Cancer; CRISPR,
clustered regularly interspaced short palindromic repeats; CTNNB1, b-
catenin (cadherin-associated protein) b1; GFP, green fluorescent protein;
GSK3, glycogen synthase kinase 3; HCC, hepatocellular carcinoma; IP,
immunoprecipitation; qRT-PCR, quantitative reverse-transcription poly-
merase chain reaction; TCF/LEF, T-cell factor/lymphoid enhancer-binding
factor; b-TrCP, b-transducin repeats-containing protein; WT, wild type.
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In normal cells, b-catenin signaling is maintained at low
levels by a destruction complex consisting of the adenoma-
tous polyposis coli (APC) tumor suppressor, scaffold pro-
teins axis inhibition protein (AXIN) 1 and 2, and the kinases
glycogen synthase kinase 3 (GSK3) and casein kinase 1a
(CK1a). In this complex, CK1a initiates b-catenin (CTNNB1)
phosphorylation at S45, followed by sequential GSK3 phos-
phorylation at T41, S37, and, finally, S33. Next, the phos-
phorylated 32DpSGXXpS37 motif promotes binding of the
ubiquitin ligase b-transducin repeats-containing proteins
(b-TrCP [BTRC]), which targets b-catenin for proteasomal
degradation. When cells are exposed to Wnt ligands, this
b-catenin breakdown complex is temporarily inhibited,
leading to the stabilization of b-catenin. As a result, it trans-
locates into the nucleus and associates with members of the
T-cell factor/lymphoid enhancer-binding factor (TCF/LEF)
family of transcription factors, thus regulating the expression
of specific downstream Wnt/b-catenin target genes.2,3
In several tumor types, this pathway is constitutively
activated through mutational (in)activation of one of the
core elements of the destruction complex. In colorectal
cancers, predominantly loss-of-function mutations are
observed in the APC gene. For these mutations, it has
become well accepted that they are selected on providing a
just-right level of b-catenin signaling that is optimal for
tumor initiation and progression.4 Other tumor types, such
as hepatocellular and endometrial carcinomas,5–7 mainly
acquire oncogenic b-catenin (CTNNB1) mutations at the
N-terminal S/T phosphorylation residues, making the
protein more resistant to proteolytic degradation.
Recently, Rebouissou and coworkers8 showed that, for
these CTNNB1 mutations, a clear genotype-phenotype
correlation exists in liver cancer. In-frame exon 3 de-
letions that remove the entire N-terminal phosphorylation
domain and D32-S37 amino-acid alterations directly
affecting the b-TrCP recognition motif lead to highly active
b-catenin variants. T41 mutations were associated with
moderate activity, whereas S45 mutations showed a weak
but clear activation of the pathway. The reduced activity of
the latter 2 mutations is most likely the result of residual
phosphorylation of the b-TrCP interaction domain, leading
to some breakdown of these mutants.9 This liver cancer
study also included 2 more recently recognized mutational
CTNNB1 hotspots, K335I and N387K, which are located in
armadillo repeat domains 5 and 6 of the b-catenin protein,
respectively. Currently, according to the Catalogue of So-
matic Mutations in Cancer (COSMIC) Web site,10 mutations
at these residues have been observed in more than 100
individual tumors, especially those of the liver, colon, and
kidney (Figure 1 and Supplementary Table 1). They lead to
a weak but significant enhancement of b-catenin
signaling.8,11 However, the mechanism leading to their
increased activity is still unknown.12 Here, by exploringpotential mechanisms that may explain their increased
signaling propensity, we identify a novel mechanism of
enhanced b-catenin signaling.Methods
Catalogue of Somatic Mutations in Cancer
Database Analysis
To obtain the cancer-related CTNNB1 mutations depicted in
Figure 1, we analyzed the COSMIC Web site (https://cancer.
sanger.ac.uk/cosmic/gene/analysis?ln¼CTNNB1), filtering it on
amino acids 310–440. Data were updated until January 2019.
Plasmids and Construction
N-terminal FLAG-tagged b-catenin variants were con-
structed by using the pcDNA 50 UT-FLAG vector, as previously
described.13 Briefly, the constructs of WT (WT), S33Y, and exon
3 deletion were generated by using the Gibson assembly
method New England Biolabs (NEB). Based on the WT back-
bone, all other variants (G34V, S37F, T41A, S45P, Y333F,
E334K, K335I, K335T, R376H, W383G, W383R, N387K, and
R582W) were constructed by using Q5 site-directed mutagen-
esis (NEB). The green fluorescent protein (GFP)–APC (1199-
2167) plasmid was generated by cloning a 2.9-kilobase EcoRI
Figure 1. Oncogenic hotspot mutations observed in armadillo repeats 5 and 6 of b-catenin. Three amino acids are commonly
mutated in cancers: K335, W383, and N387. (A) An overview of all reported amino acid substitutions along the b-catenin
protein. (B) Mutations restricted to amino acids 310–440. Details such as involved cancer types can be explored interactively
on the COSMIC Web site, but are also presented in Supplementary Table 1. The following alterations have been observed at
least 4 times: Y333F, 7 times; E334K, 8 times; K335T, 18 times; K335I, 46 times; R376H, 4 times; W383C, 12 times; W383R, 12
times; W383G, 7 times; and N387K, 40 times.
















fragment of mouse Apc into pEGFP-C1. It encodes all 20 amino
acid b-catenin–binding repeats and all AXIN-binding domains of
APC. pcDNA3.1 myc-mbTrCP WD1-7 (241-569) was a gift from
Michael Ruppert (#62977; Addgene, Watertown, MA).14 pCS2-
MT mouse Axin (Axin MTFu1) was a gift from FrankCostantini (Addgene #21287) and encodes an N-terminal
6xMyc-tagged mouse AXIN1 variant of amino acid 832.15 The
pT3-EF1a-b-catenin-K335I and pT3-EF1a-b-catenin-N387K
constructs were generated by subcloning a Bsu36I-EcorI frag-
ment in the pT3-EF1a-b-catenin-WT plasmid (with N-terminal




LIVERMyc-tag). pT3-EF1a-c-Met and pCMV/sleeping beauty trans-
posase (pCMV/SB) plasmids have been described previously.16Mice and Hydrodynamic Tail Injection
Hydrodynamic tail vein injection was performed basically
as previously described.17–19 Briefly, 20 mg of either pT3-EF1a-
b-catenin-WT, K335I, or N387K construct was mixed with 20
mg pT3- EF1a-c-Met and 1.6 mg pCMV/SB in 2 mL saline. This
solution was injected in the lateral tail vein of 6- to 8-week-old
WT FVB/N mice purchased from The Jackson Laboratory
(Sacramento, CA). Mice were monitored via abdominal palpa-
tion every 3 days. The mice were killed and were considered to
be dead when they developed a palpable abdominal mass,
based on the Institutional Animal Care and Use Committee
protocol. Mice were housed and fed in accordance with pro-
tocols approved by the Committee for Animal Research at the
University of California, San Francisco. Livers and tumors were
analyzed basically as previously described (see Supplementary
Methods).17–19Clustered Regularly Interspaced Short
Palindromic Repeats/Cas9 Mediated Knock-In of
CTNNB1 Mutations
Previously, we generated SNU449 clones in which the
AXIN1 p.R712* mutation was successfully repaired with clus-
tered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 technology (manuscript submitted). Clone-20
thereof and HEK293 cells were used to knock in b-catenin
S37F and K335I mutations, as described in the Supplementary
Methods.Half-Life Determination
N-terminal FLAG-tagged b-catenin variant plasmids (200
ng) were cotransfected into HEK293 cells with pEGFP-C1 (50
ng) using FuGENE HD. The pEGFP-C1 plasmid generates a
highly stable GFP protein serving as loading control. After 24
hours, the cells were treated with cycloheximide (50 mg/mL)
for 0, 30, 60, 90, 120, and 150 minutes. Next, cells were washed
with cold phosphate-buffered saline 2 times and lysed in 2
Laemmli sample buffer (120 mmol/L Tris-Cl pH 6.8, 20%
glycerol, 4% sodium dodecyl sulfate) with 0.1 mol/L dithio-
threitol, and heated for 5 minutes at 95C.Immunoprecipitation
For the immunoprecipitation (IP) assays using expression
plasmids, HEK293 or HCT116 cells were seeded in 6-well
plates before transfection. When reaching 60%–80% conflu-
ence, 1 mg N-terminal FLAG-tagged b-catenin variant plasmids
were cotransfected with either 1 mg of APC-, AXIN- or bTrCP-
expression plasmids using FuGENE HD (Promega, The
Netherlands). After 24 hours, FLAG-tagged b-catenin was
immunoprecipitated with ANTI-FLAG M2 Affinity Gel (Sigma-
Aldrich, St Louis, MO). Knock-in cell lines were seeded in 15-
cm round plates, lysed, and incubated with primary antibody,
which was immunoprecipitated with Pierce Protein A/G
Magnetic beads (Thermo Fisher Scientific, Waltham, MA).
Details of the IP protocols can be found in the Supplementary
Methods.Western Blotting, Antibodies, and Quantification
Fluorescent Western blotting and quantitative analysis
were performed basically as previously described.20 Primary
antibodies are listed in the Supplementary Methods. As sec-
ondary antibodies, we used anti-rabbit or anti-mouse IRDye-
conjugated antibodies (LI-COR Biosciences, Lincoln, NE).
Protein intensity was detected with the Odyssey 3.0 Infrared
Imaging System and analyzed by Image Studio Lite, version 5.2
(LI-COR). For APC Western blot analysis, we used Immobilon
ECL Ultra HRP substrate (Merck Millipore, Billerica, MA).
Membranes for ECL detection were blocked and incubated
using Immobilon Block-PO reagent (Merck Millipore).
b-Catenin Reporter Assays
HEK293 cells were seeded in 24-well plates to reach approx-
imately 50%–70%confluency on the dayof transfection. Eachwell
was transfected with 5 ng of the b-catenin expression vectors, 250
ng TOPflash or FOPflash, and 10 ng CMV-Renilla using Fugene HD
(Promega, Madison, WI). For the knock-in HEK293 and SNU449
cells, we used the more sensitive Wnt-Responsive Element/
Mutant Responsive Element (WRE/MRE) reporters, using 12-well
and 6-well plates, respectively. After 2 days, luciferase activities
were measured in a LumiStar Optima luminescence counter (BMG
LabTech, Offenburg, Germany) and normalized for transfection
efficiency by using the Dual Luciferase Reporter Assay system
(Promega), according to the manufacturer’s instruction. Trans-
fections were performed in triplicate, and the mean and standard
error were calculated for each condition. The b-catenin reporter
activities are shown as TOP/FOPflash or WRE/MRE ratios.
Structure Analysis
Structures were analyzed and figures were created with the
PyMOL Molecular Graphics System, version 2.0 (Schrödinger,
New York, NY). Overlays were created by superimposing
b-catenin (chain A) from the b-catenin–TCF complex (1G3J.pdb),
b-catenin–E-cadherin complex (1I7W.pdb), or the b-catenin–
AXIN complex (1Q27) onto chain A of the b-catenin–
phosphorylated 20–amino acid APC complex (1TH1.pdb).
Statistical Method
Expression differences tested by quantitative reverse-
transcription polymerase chain reaction (qRT-PCR), and lucif-
erase assays were tested by unpaired t test. Statistical differ-
ences are depicted as follows: *P < .05; **P < .01; ***P < .001;
****P < .0001. All statistical analyses were performed using
GraphPad Prism 6 (GraphPad Software, San Diego, CA).
Results
K335I and N387K b-Catenin Variants Are Potent
Inducers of Hepatocellular Carcinoma Formation
in Mice
To directly demonstrate the oncogenic potential of the
b-catenin K335I and N387K variants, we hydrodynamically
injected them in the tail vein of mice.21 WT b-catenin was
taken along as control. All variants were cotransfected with
c-Met because previous work showed that oncogenic b-cat-
enin alone is insufficient for hepatocellular carcinoma (HCC)
development.16,17 In strong contrast to the mice injected with
















WT b-catenin, all K335I/N387K injected mice became mori-
bund 6–7 weeks after injection, showing a massive increase
in liver weight and tumor burden (Figure 2A). Histologically,
we observed the presence of well- to moderately differenti-
ated HCC with solid or macrotrabecular growth patterns
(Figure 2A and Supplementary Figure 1), in accordance with
previous observations.16,17 Lesions are positive for the he-
patocyte marker HNF4a but negative for the biliary marker
CK19 (Supplementary Figure 2). In WT injected mice, only
occasional HCC-like foci were observed. This marked differ-
ence in oncogenic potential was confirmed by immunohisto-
chemical analysis of the proliferation marker Ki-67 (Figure 2B
and C) and qRT-PCR analysis showing an elevated expression
of the HCC markers Gpc3 and Afp (Figure 2D).
Staining for b-catenin showed a predominant membra-
nous location (Figure 3A). Occasionally a weak cytoplasmic
or nuclear staining was observed, especially for the N387K
variant. This result was confirmed with an antibody
detecting the Myc tag present in the construct (Figure 3A).
The lack of a prominent nuclear accumulation is in line with
previous observations for the weak b-catenin S45Y
variant.17 Nevertheless, we observed a strong increase in
the (liver-specific) b-catenin target genes Axin2, Tbx3, and
Glul (Figure 3B), the latter also confirmed by immunohis-
tochemical staining for glutamine synthetase (Figure 3C).
Taken together, these results show that both the K335I
and N387K variants, compared with WT b-catenin, have a
strong potential to induce liver tumor formation in mice,
associated with a clear induction of target gene expression.
Half-Life of b-Catenin Mutants Correlates With
Their Activation Potential
The signaling activity of b-catenin is strongly regulated by
proteolytic degradation. Therefore, we analyzed the half-lives
of various commonly observed b-catenin variants in com-
parison with WT protein (Supplementary Figure 3). Inter-
estingly, K335I and N387K variants show a similar protein
stability as WT b-catenin, with half-lives between 65 and 100
minutes. The S45P mutation increases the half-life up to 110
minutes, and mutations affecting the D32-S37 b-TrCP binding
motif and the exon 3-deletion variant extends it to more than
2 hours. Thus, these analyses show that protein stability
largely correlates with the reported signaling activities; that
is, mutants with weak enhanced signaling capabilities show a
turnover comparable to the WT protein, whereas more active
signaling variants show a clearly increased half-life.
K335 and N387 Variants Are Not Affected in
N-Terminal Phosphorylation and b-TrCP Binding
b-catenin protein stability is largely regulated by
sequential N-terminal S/T phosphorylation. Hence, we
determined the phosphorylation status of b-catenin variants
transfected in HEK293 cells (Figure 4A). The exon 3–deletion
variant lacking all S/T residues cannot be recognized by any
of the phospho-antibodies. All other variants are readily
phosphorylated at S45 comparable to the WT protein, except
for the S45P mutant. In contrast, the GSK3-mediated phos-
phorylation at residues T41, S37, and S33 is reduced in allS33 to S45 mutants. In accordance with previous reports, we
still observed some residual S/T phosphorylation in all these
variants.9 Importantly, in this overexpression assay, the K335
and N387 mutants showed no obvious deviation from the
phosphorylation pattern observed for the WT protein.
Next, we determined the binding capacity of b-TrCP to
each variant in HEK293 cells. Our IP protocol resulted in a
weak unspecific binding of Myc-tagged b-TrCP in the negative
control (lane 2 of Figure 4B). For the S33-S45 mutants,
similar or, at most, slightly increased levels of coimmuno-
precipitated b-TrCP were observed, whereas both K335 and
N387 mutants showed equal binding capabilities, comparable
to the WT protein. Overall, these analyses show that K335I
and N387K mutant proteins are not seriously affected in N-
terminal phosphorylation and binding to b-TrCP.
K335 and N387 Variants Show Reduced Binding
to the Adenomatous Polyposis Coli Protein
Because protein half-life, N-terminal phosphorylation, and
b-TrCP binding are not clearly affected for the K335I and
N387K variants, we sought for an alternative explanation
explaining their increased signaling behavior. Both residues are
located in armadillo repeats 5 and6 ofb-catenin in the center of
the protein. In total, 12 armadillo repeats (residues 141–664)
form a superhelix with a positively charged groove, which can
associatewith a large number of proteins.2We focused onwell-
established binding partners at the cell membrane, nucleus,
andwithin the destruction complex, that is, E-cadherin, TCF7L2
(also known as TCF4), AXIN1, and APC. Except for AXIN1, these
have all been shown to bind an extended area encompassing
both K335 and N387 residues (Figure 5A). Within epithelial
cells, most b-catenin is captured at the cell membrane through
interactions with cadherins. Hence, a reduced binding affinity
between b-catenin and E-cadherin is expected to increase the
signaling pool of b-catenin, possibly leading to enhanced nu-
clear signaling. However, IP of WT and the K335I and N387K
variants from HCT116 cells showed no altered binding to E-
cadherin (Figure 5B). Alterations in binding to TCF7L2 within
the nucleus are also expected to affect activation of b-catenin
target genes, but again, we failed to show any difference be-
tween the tested variants (Figure 5B). Likewise, binding of
cotransfected MYC-tagged AXIN1 was not affected by both
mutations (Figure 5C). In contrast, binding of a cotransfected
GFP-tagged APC fragment was strongly impaired for the K335I
and N387K mutants (Figure 5D). Taken together, these IP ex-
periments show that, compared with WT b-catenin, both mu-
tants associate less strongly with APC, one of the core proteins
of the destruction complex.
Endogenous Expression in Cell Lines Confirms
Increased Signaling and Reduced Affinity for
Adenomatous Polyposis Coli Protein
Because overexpression may affect the stoichiometry of
the b-catenin breakdown complex, we wished to confirm our
results at endogenous expression levels. Previously, we
generated SNU449 liver cancer cells in which the AXIN1
p.R712* mutation was successfully repaired with CRISPR/
Cas9 technology (manuscript submitted), so that no known
Figure 2. K335I and N387K b-catenin variants are potent inducers of HCC development in mice. (A) Hydrodynamic tail vein
injection of b-catenin–K335I and N387K variants resulted in a strong increase of liver weights within 6–7 weeks, in contrast to
WT b-catenin–injected animals (n ¼ 5 each). All variants were cotransfected with c-Met. H&E staining showed multiple large
foci of well-differentiated HCCs with solid or macrotrabecular growth patterns. (B) Immunohistochemical analysis for the
proliferation marker Ki67 and (C) quantification of 5 representative fields. (D) Expression of HCC markers Gpc3 and Afp was
evaluated by qRT-PCR in normal (CTR) and transfected livers. All data are presented as mean ± standard deviation. *P < .05;
**P < .01; ***P < .001; ****P < .0001; ns, nonsignificant.





March 2020 Armadillo Repeat 5/6 Mutations of b-Catenin 1035b-catenin activating mutations remain. In these and HEK293
cells, we successfully knocked in the K335I mutation. For
direct comparison, we also generated cells carrying the strong
S37F mutation (see Supplementary Table 2 for clone details).Figure 3. Immunohistochemical analysis of b-catenin patterns
ciated Myc-tag shows a predominant membranous location for
stronger cytoplasmic staining is observed, especially for the N3
Axin2, Tbx3, and Glul. RNA isolated from previously injected b-
(C) Immunohistochemical confirmation of glutamine synthetaseAttempts to generate N387K knock-in cell lines failed.
Western blot analysis of SNU449 mutant cells showed a
modest increase in total b-catenin levels, especially for the
S37F mutant cells (Figure 6A), whereas in HEK293, this wasand target gene expression. (A) IHC for b-catenin and asso-
transfected WT, K335I, and N387K variants. Occasionally, a
87K variant. (B) qRT-PCR analysis of b-catenin target genes

















Figure 4. K335 and N387 variants are not affected in N-terminal phosphorylation and b-TrCP binding. (A) FLAG-tagged b-catenin
variants were transfected in HEK293 and subjected to Western blotting with phospho-specific b-catenin antibodies
(Supplementary Table 7). Endogenous b-catenin is visible in the mock and exon 3–deletion transfected lanes, which was sub-
tracted from the transfected variants. Signal of WT protein was set to 1, to which all other values were normalized. K335I and
N387K variants are similarly phosphorylated as WT protein. (B) FLAG-tagged b-catenin variants were cotransfected with Myc-
tagged b-TrCP into HEK293 cells. Two hours before FLAG-IP, cells were treated with the proteasome inhibitor MG132. The
amount of coimmunoprecipitated b-TrCP was determined after normalization with b-TrCP input signal. Signal of IP obtained with
Myc-tagged b-TrCP alone was set to 1. K335I and N387K variants are not affected in their association with b-TrCP.




LIVERthe case only for S37F clones. All K335I clones showed a
significant increase in b-catenin reporter activity (Figure 6B),
although not as pronounced when compared with the S37F
variant. These results were confirmed with AXIN2 qRT-PCR
(Supplementary Figure 4). IP of endogenous APC using 2
independent antibodies confirmed the reduced binding of the
K335I variant (Figure 6C). These results confirm the
increased signaling propensity of the armadillo variants
through reduced APC binding at endogenous levels as well.Protein Structures of b-Catenin Complexes
Provide a Rationale for Reduced Binding of
Mutant b-Catenin Selectively to the
Adenomatous Polyposis Coli Protein
To identify potential mechanisms underlying the
differential binding of AXIN1, APC, TCF7L2, and E-cadherin
to both mutants, we analyzed available protein struc-
tures of b-catenin in complex with fragments of these
proteins (Supplementary Figure 5A).22–25 In all complexes,b-catenin–K355 forms a hydrogen bond with a backbone
carbonyl oxygen of the bound partner protein
(Supplementary Figure 5B–D). In addition, K335 forms
specific interactions with sidechains from the bound pro-
teins, which are different for each partner and depend on its
phosphorylation status. The 7 20–amino acid repeats
(AARs) of APC contain a conserved SxxxSLSSL motif that is
phosphorylated on multiple serine residues by GSK3/CK1
when APC is associated with AXIN, which strongly increases
the binding to b-catenin.25–27 Interestingly, in the b-catenin–
APC complex, the positively charged K335 sidechain forms
ionic interactions and hydrogen bonds with 2 negatively
charged phosphorylated serines (pS1504 and pS1507) in
the APC 20-AAR motif (Supplementary Figure 5B), all of
which are lost when mutated to isoleucine or threonine. In
the b-catenin–TCF complex, no serines are available within
this region for phosphorylation; instead, K335 forms a sin-
gle ionic interaction with the negatively charged sidechain
of D40 (Supplementary Figure 5C). E-cadherin carries a
phosphorylated serine (S692) at the corresponding position
Figure 5. K335I and N387K variants selectively show reduced binding to APC. (A) Schematic representation of the reported
binding domains of APC, AXIN, TCF/LEF, and E-cadherin to the armadillo repeat region of b-catenin. Positions of K335I and
N387K mutations are indicated by arrows. pS indicates serine phosphorylation present at binding interface of APC or
E-cadherin. (B) FLAG-tagged WT, K335I, and N387K b-catenin variants were transfected in HCT116 cells. Myc-tagged-AXIN1
and nontransfected cells were used as negative controls. After FLAG-IP, endogenous E-cadherin and TCF7L2 were shown to
bind equally to WT b-catenin and both variants. (C) The same b-catenin variants were cotransfected with Myc-tagged AXIN1
into HEK293 cells. All variants bind equally to AXIN1. (D) Cotransfection with GFP-APC in HEK293 cells. GFP-APC expresses a
GFP-tagged murine APC fragment (amino acids 1199–2167) encoding all the 20–amino acid b-catenin–binding repeats and
AXIN-binding domains. Both the K335I and N387K variants associate much more weakly to GFP-APC. In the latter 2 ex-
periments, cotransfection of GFP-APC and Myc-AXIN1 was used as negative IP control. All transfections experiments were
performed 3 times with identical results.
















of APC-Ser1507 and forms an ionic bond with K335; how-
ever, it carries an apolar A688 at the position corresponding
to pS1504 in APC (Supplementary Figure 5D). In AXIN, only
hydrophobic residues are present at this interface (not
shown), which form weak van der Waals contacts with the
polar amine of K335 but might form more favorable con-
tacts when the lysine is mutated to hydrophobic isoleucine.
To summarize, K335 forms more energetically favorableinteractions with APC than with any of the other proteins,
explaining the observed relatively large effect of K355 mu-
tation on APC binding specifically.
The N387K mutation will influence hydrogen bond for-
mation between b-catenin and the peptide backbone of APC,
LEF/TCF, and E-cadherin and is expected to reduce the
strength of the interaction in all complexes (Supplementary
Figures 5E and 6A and B). In this case, the structural
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Selective Loss of APC Binding Is a Common
Feature of Armadillo Repeat 5 and 6 Mutations
Currently, more than 150 individual neoplasias have been
identified carrying amino acid alterations in repeats 5/6 of b-
catenin (Figure 1 and Supplementary Table 1). Besides the
K335 and N387 amino acid alterations, residues Y333, E334,
R376, and especially W383 are also mutated in neoplasias
regularly. Within the b-catenin structure, these residues are
organized in 2 clusters in close proximity to each other
(Figure 7A). We generated expression plasmids for these
variants and tested them for binding to APC, TCF7L2, and E-
cadherin. We also took along 1 commonly observed R582W
variant (n ¼ 14) located toward the end of the armadillo
repeats. As can be seen in Figure 7B and C, most of these
newly generated mutants show loss of APC binding, but all
retain binding to TCF7L2 and E-cadherin. The only exceptions
are the E334K and R582W variants, which behave identical to
WT protein with respect to APC binding.
Next, we performed b-catenin reporter assays for all of
the armadillo repeat 5/6 variants, taking S33Y and WT b-
catenin along as controls (Figure 7D). All variants showing a
reduced binding to APC, yield a 1.5–3-fold higher induction
of reporter activity compared with the WT, whereas the
E334K and R582W variants behave similar to the WT.
Importantly, analysis of the available protein structures
shows that all additional mutated residues associated with
increased signaling (Y333, R376, and W383), form direct in-
teractions with APC (Figure 7E and F). In fact, binding of
cluster-1 residues (Figure 7A and E) to APC creates an exten-
sive network inwhich oppositely charged groups alternate and
form multiple ionic interactions and hydrogen bonds with
neighboring residues. Any mutation in this network will affect
several highly optimized interactions, explaining the relatively
large effect on APC binding that we observed. E334 does not
form direct interactions with APC, possibly explaining its lack
of increased signaling when mutated, although it may be
involved in properly orienting the R376 residue.
In TCF and E-cadherin, the highly cooperative cluster-1
network is much reduced in size due to replacement of
crucial serine sidechains (that are phosphorylated in APC)
with hydrophobic residues (V44 in TCF and A688 in E-
cadherin) (Supplementary Figure 6C and D). These apolar
residues cannot favorably interact with the polar sidechains
in cluster-1, which means that the contribution of this
cluster to the stability of TCF and cadherin complexes with
b-catenin is weaker than for APC, explaining why cluster-1
mutations have a relatively smaller effect on their binding.=
Figure 6. Endogenous expression in cell lines confirms increased
K335I and S37F mutation in SNU449 cells leads to a modest inc
restricted to S37F clones. Numbers in brackets refer to the numb
are homozygous in all cases. (B) b-catenin luciferase reporter as
are presented as mean ± standard deviation. **P < .01; ***P < .0
comparison with the parental line. (C) IP of endogenous APC s
bodies were used. Vertical dashed lines indicate removed irreleIn cluster-2 (Figure 7A and F), the sidechain of W383
forms van der Waals contacts with 2 threonine residues on
APC, forming a small hydrophobic core that contributes to
complex stability. Mutation of W383 will disrupt this ener-
getically favorable region, resulting in loss of APC binding.
TCF residues do not interact with the sidechain of W383 in
b-catenin, and its mutation will not affect stability of the TCF
complex (Supplementary Figure 6E). The situation is less
clear in E-cadherin, in which favorable interactions between
W383 from b-catenin and Y681 from E-cadherin are formed
(Supplementary Figure 6F).Armadillo Repeat 5 and 6 Mutations Co-occur
With Other b-Catenin Enhancing Mutations in
Colorectal, but not in Hepatocellular, Carcinomas
Mutations in the repeats 5 and 6 region of b-catenin
have been mainly reported in liver, colon, and kidney
tumors,5,8,28–31 and anecdotally in several other tumor
types. The stronger activating b-catenin mutations encom-
passing exon 3 are known to occur in a mutually exclusive
fashion with disease-causing APC mutations,32 showing that
either mutation is sufficient to drive tumorigenesis. When
we analyzed colorectal cancers carrying armadillo repeat
5/6 mutations for concomitant defects in other genes linked
to b-catenin signaling, these were observed in 11 out of 13
cancers (Supplementary Table 3). Seven out of 13 cancers
carried APC mutations, but, interestingly, 3 out of 7 express
a truncated APC protein that is expected to retain a signif-
icant level of b-catenin regulation that is 3 or more of the 20
AARs.4 Three other cancers carry truncating AXIN2 or
RNF43 mutations that are generally also considered to be
weak signaling activators. A similar analysis of 20 HCCs
identified no accompanying b-catenin signaling activating,
except for a single truncating ZNRF3 mutation
(Supplementary Table 4). Thus, in contrast to liver cancers,
the armadillo hotspot mutations observed in colorectal
cancers are often accompanied by other weak mutations
that may synergistically enhance b-catenin signaling to
levels, supporting tumor growth.Discussion
The b-catenin signaling pathway is one of the most
commonly deregulated pathways among cancers.1 In colo-
rectal cancers, this is predominantly accomplished by
inactivating APC mutations, whereas in liver cancers,
for example, aberrant activation has been mainly
attributed to activating mutations in the CTNNB1 gene
(20%–25%).4,7,33–35 The exon 3–related b-catenin muta-
tions acquire enhanced signaling activities by interferingsignaling and reduced affinity for APC. (A) Introduction of the
rease in total b-catenin protein levels. In HEK293 cells, this is
er of CTNNB1 alleles expressing that variant. HEK293 clones
say of all available clones. WRE/MRE ratios are shown. Data
01; ****P < .0001. The bottom half shows the K335I clones in
hows reduced binding of K335I. Two independent APC anti-
vant lanes. CTR, control; IgG, immunoglobulin G.




LIVERwith proper N-terminal phosphorylation and subsequent
proteolytic degradation. More recently, mutations in the
armadillo repeat domains 5 and 6 of b-catenin have been
identified in a substantial number of cancers, especially
those of the liver. Here, we provide direct evidence that
these mutants are potent inducers of HCC development in
mice. In addition, we uncover a novel mode of b-catenin
activation for these mutants, that is, they reduce the binding
to APC while simultaneously retaining binding to TCF/LEF.
The latter is important to allow sufficient enhancement of
the b-catenin target genes driving tumor formation. A
weaker binding to APC is expected to increase the signaling
pool of b-catenin, enhancing the expression of b-catenintarget genes driving tumor formation. However, if such a
mutation would simultaneously reduce binding to the
essential nuclear TCF/LEF transcriptional cofactors, the
overall activation of target genes would not increase or even
be reduced compared with WT b-catenin. In accordance
with this, mutation of K312 and K435 residues is rarely
observed, because these so-called charged buttons of b-
catenin are essential for binding of most proteins to the
armadillo superhelix by forming an ionic bond to conserved
glutamate residues.22,36
When mapping the mutated residues on the protein
structure of b-catenin, 2 clusters emerge that appear to be
critical binding domains with APC (Figure 7A). Cluster-1 is
centered around K335 and further involves residues Y333 and
R376. Previously, these were all identified to directly interact
with phosphorylated 20–amino acid repeats of APC but also, to
some extent, with cadherins and TCF/LEF.25 However, the IP
experiments show that their mutation selectively results in
loss of APC binding, while leaving binding to TCF and E-cad-
herin unaffected. For the K335 residue itself, the structural
analyses provide a rationale because it forms more energeti-
cally favorable interactions with APC than with any of the
other proteins. Likewise, the structural analyses show that
Y333 is not critical for TCF binding, whereas R376 is not
important for cadherin binding. It is interesting to consider
that an extensive ion-pair network is formed upon b-catenin–
APC complex formation, while much smaller, fragmented
networks are present in the TCF and E-cadherin complexes.
Ion-pair networks are cooperative entities from which
removal of a single residue through mutation will have a
relatively large effect on the stability of the region.37–39 This=
Figure 7. Increased signaling and selective reduction of APC
binding for most armadillo repeat 5/6 variants. (A) Surface
representation of b-catenin in gray with bound APC as tube
representation in blue. K335 in cluster-1 is colored light blue,
with surrounding residues Y333, E334, and R376 in light
green. N387 in cluster-2 is colored red, and the other
commonly mutated W383 is colored orange. (B) Cotrans-
fection of indicated FLAG-tagged b-catenin variants with
GFP-APC in HEK293 cells. After FLAG-IP, most of the
commonly observed armadillo repeat 5/6 variants associate
much more weakly to GFP-APC. (C) FLAG-tagged b-catenin
variants were transfected in HCT116 cells. After FLAG-IP, all
variants are shown to bind equally to endogenous TCF7L2
and E-cadherin. (D) A TOP-FOPflash b-catenin reporter assay
in HEK293 cells shows that all armadillo repeat 5/6 variants
that bind more weakly to APC show a 1.5–3-fold increased
signaling compared with WT b-catenin. TOP-FOPflash ratios
are shown. Experiments were performed in triplicate and
repeated twice. Data are presented as mean ± standard de-
viation. ***P < .001; ****P < .0001. (E) Details of the cluster-1
complex, with b-catenin in gray and APC in blue. A 6-residue
ion-pair network is formed between E334-R376;R376-
pS1504;pS1504-K335;K335-pS1507;pS1507-K292. In fact,
the network is even bigger and extends beyond K292 (not
shown). Hydrogen bonds are indicated with dashed lines.
(F) Details of the cluster-2 complex. W383 packs against the
hydrophobic methyl-groups (blue carbons) of the sidechains
of T1493 and T1496 and so forms favorable van der Waals
interactions (curved lines).
















may explainwhy themutation of K335 has amuch larger effect
on complex formationwithAPC (inwhich it is a central residue
formingmultiple ionic bonds) than on complex formationwith
TCF and E-cadherin (inwhich the lysine is a peripheral residue
in the smaller network).
Cluster-2 involves residues W383 and N387. Previously,
the W383 residue was already identified as important for
APC binding because a W383A mutant failed to bind APC
while retaining LEF/TCF7L2 association,40 which is in
accordance with the structural analyses, because TCF does
not interact with W383. For the commonly mutated N387
residue, the structural analysis provided no direct clues
explaining the reduced binding of, specifically, APC. Never-
theless, our IP and structural analyses provide clear evi-
dence that both clusters are more relevant for APC binding
than for TCF and cadherins.
Despite 2 decades of research, the exact mechanism
through which APC functions in the destruction complex is
still not fully understood. Several models not necessarily
excluding each other have been proposed.41,42 One model
proposes that APC is involved in sequestering b-catenin
within the cytoplasm, thereby preventing it from entering
the nucleus.43,44 Other models suggest that APC protects S/
T phosphorylated b-catenin from dephosphorylation by
PP2A, that it may be required to interface b-catenin with the
ubiquitin and proteasome machinery, or that it is required
to displace AXIN from phosphorylated b-catenin to allow a
new cycle of b-catenin breakdown.24,45,46 Whichever model
turns out to be true, in all cases, a weaker association of
mutant b-catenin with APC will make the process less effi-
cient and effectively lead to more signaling.
How to reconcile the weak APC/mutant b-catenin
interaction with the rather modest increased signaling ac-
tivity associated with these variants? Current models of
APC’s contribution to the destruction complex propose that
direct binding of b-catenin to APC is not absolutely required
for a proper level of b-catenin turnover, as long as APC is
present within the destruction complex—for example,
through binding to AXIN.41,42,44,47 This partial functional
redundancy between APC and AXIN is most likely also
responsible for keeping the signaling activity of the arma-
dillo repeats 5/6 mutants in check, although it will be less
efficient when compared with WT b-catenin.
Mutations in this region of b-catenin have been mainly
reported in liver cancers, Wilms tumors, and tumors of the
large intestine,5,8,28–31 and anecdotally in several other tu-
mor types, but their true frequency is probably under-
estimated because, in the past, CTNNB1 mutation analysis
was largely restricted to the exon 3 hotspot. Therefore,
whole-exome or -genome mutational analyses that are
becoming more routine procedures for tumor investigations
nowadays are likely to more frequently uncover these spe-
cific mutations. Given their weak activation nature, these
mutations are more likely going to be identified in tumor
types that require a minimal to moderate activation of the
pathway to support their growth.4,48,49 In that respect, their
presence in colorectal cancer is somewhat surprising
because these cancers generally select for higher b-catenin
signaling levels.4 Our analysis shows, however, that incolorectal cancer, the armadillo hotspot mutations are often
accompanied by other (weak) mutations that synergistically
may enhance b-catenin signaling to levels supporting tumor
growth. A similar scenario may be at work for Wilms tu-
mors, in which the armadillo repeat 5/6 mutations often
associate with those of WTX (official name, AMER1),31 also
leading to a modest signaling enhancement. In liver cancers,
however, the weak signaling associated with these armadillo
repeat variants appears to be sufficient to support tumor
growth because they are not clearly associated with defects
in other Wnt/b-catenin signaling–related components.
This latter observation is also in line with our tumor
induction experiments in mice and the analysis of SNU449
and HEK293 cell lines with knock-in mutations. In a direct
comparison, endogenous levels of the K335I mutant are
clearly more potent inducers of b-catenin signaling than WT
b-catenin, but they are rather weak in comparison with the
strong S37F mutation. Nevertheless, within 6–7 weeks after
injection, they lead to a massive HCC formation, which is
comparable in timeframe with the S45Y and D90N-b-cat-
enin variants.17 However, immunohistochemical analysis
showed no clear nuclear accumulation for the K335I and
N387K variants. Similar observations have been made for
K335/N387 mutant human liver tumors, which also lack a
clear nuclear b-catenin accumulation associated with a
weak activation of target genes.8 Combined, these results
show that a strong nuclear presence is no prerequisite for
efficient liver cancer formation. In support of this, we have
recently shown that liver specific loss of AXIN1 requires b-
catenin to induce hepatocarcinogenesis, which, however,
was associated with only a weak activation of b-catenin
target genes.18 Buchert et al48 have shown that late-onset
hepatocellular tumors were present in all mice carrying a
hypomorphic APC mutation associated with just a modest
increase in b-catenin signaling, and tumor formation was
absent or largely prevented with slightly increased or
decreased signaling. All of these examples show that only
modest increases in b-catenin signaling may nevertheless be
relevant for hepatocellular tumorigenesis.
In conclusion, our molecular and structural analyses un-
cover a novel mutational mechanism of enhanced b-catenin
signaling. In contrast to the N-terminal mutations in b-cat-
enin that directly impair its phosphorylation by GSK3/CK1a
or binding to b-TrCP, the hotspot mutations within armadillo
repeats 5 and 6 lead to enhanced signaling through reduced
binding to APC while simultaneously retaining the interac-
tion with their nuclear TCF/LEF transcriptional cofactors.
The latter is important to allow sufficient enhancement of b-
catenin target genes driving tumor formation. A second dif-
ference with the N-terminal mutants appears to be that they
often co-occur with other mutations affecting b-catenin
signaling, at least in colorectal and Wilms tumors.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2019.11.302.
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Supplemental Methods and Reagents
Additional Methods for Analysis of Mouse Livers
and Tumors: H&E Staining and
Immunohistochemistry
Mouse liver tissues were fixed in 4% para-
formaldehyde overnight at 4C for subsequent paraffin-
embedding. Sections were cut at 5-mm thickness and
then used for H&E staining and immunohistochemistry.
H&E staining was performed to determine characteris-
tics of neoplastic foci. For immunohistochemistry, anti-
gen retrieval was performed in sodium citrate buffer (pH
6.0) by placement in a microwave on high for 10 mi-
nutes, followed by a 20-minute cooldown at room tem-
perature. After a blocking step with the 5% goat serum
and Avidin-Biotin blocking kit (Vector Laboratories,
Burlingame, CA), the slides were incubated with primary
antibodies (Supplementary Table 5) overnight at 4C.
Slides were then subjected to 3% hydrogen peroxide for
10 minutes to quench endogenous peroxidase activity.
Subsequently, the biotin conjugated secondary antibody
(Life Technology, Waltham, MA) was applied at a 1:500
dilution for 30 minutes at room temperature. Immu-
nostainings were visualized using the Vectastain Elite
ABC Kit (Vector Laboratories) using 3,30-dia-
minobenzidine tetra hydrochloride as the substrate
(Dako North America, Carpinteria, CA). Slides were
counterstained with hematoxylin.
RNA Extraction and Real-Time qRT-PCR
Total mRNA was extracted from mouse liver tissues
using the Quick RNA miniprep kit (Zymo Research,
Irvine, CA). Complementary DNA was generated using
the 5 iScript RT Supermix (Bio-Rad, Hercules, CA), ac-
cording to the manufacturer’s instructions. Messenger
RNA (mRNA) expression was determined by qRT-PCR
using SYBR Green Master Mix (Applied Biosystems,
Foster City, CA) in an QuantStudio 6 Flex system
(Applied Biosystems, Waltham, MA). Expression of each
specific gene mRNA was normalized with the 18S ribo-
somal RNA. Thermal cycling conditions included an
initial hold period at 95C for 10 minutes, which was
followed by a 3-step PCR program of 95C for 15 sec-
onds, 60C for 1 minute, and 72C for 30 seconds, for a
total of 40 cycles. Primers used in this study are shown
in Supplementary Table 6.
Cell Culture
HEK293, HCT116, and SNU449 cells and all their
derivatives were maintained in Dulbecco’s modified Eagle
medium (Lonza, Breda, The Netherlands) supplemented
with 10% fetal bovine serum (Sigma-Aldrich). Identity of
cell lines was confirmed by short tandem repeats (STR)
genotyping, and all lines were mycoplasma free.
Clustered Regularly Interspaced Short
Palindromic Repeats/Cas9-Mediated Knock-In
of CTNNB1 Mutations
Single guide RNAs (sgRNAs) were cloned into
pSpCas9(BB)-2A-GFP (PX458), a gift from Feng Zhang
(Addgene plasmid #48138)1 using standard procedures.
Single-stranded oligodeoxynucleotides (ssODNs) were
designed following the guidelines proposed by Richardson
et al,2 and were ordered as Ultramer from Integrated DNA
Technologies (Coralville, IA). Both the sgRNAs and ssODNs
are described in Supplementary Table 8. Transfections were
performed with the Amaxa Cell Line Nucleofector Kit-V
(Lonza, Basel, Switzerland) and Nucleofector IIb device,
according to the manufacturer’s instructions. In brief, 5 
106 cells were cotransfected with 2 mg PX458 and 1–2 mg
ssODN, using program T28 for SNU449 and Q1 for HEK293.
After nucleofection, complete Dulbecco’s modified Eagle
medium with 7.5 mmol/L RAD51-stimulatory compound-1
(RS-1, Sigma-Aldrich) was used for cell culture. After 48
hours, GFP-positive cells were sorted by FACS and seeded
as single cells in 96-well plates. DNA from clones grown
successfully were isolated using the QuickExtract DNA
Extraction Solution (Epicentre, Madison, WI). Each clone
was prescreened using PCRs selectively amplifying either
the WT or correctly altered sequence, according to the
method described by Harayama et al.3 Candidate clones
were subjected to Sanger sequencing and correctly modi-
fied clones were confirmed by next-generation sequencing
on the Ion Torrent Personal Genome Machine System using
amplicon fusion primers.
Details of Immunoprecipitation Experiments
For the IP experiments using expression plasmids,
HEK293 or HCT116 cells were seeded in 6-well plates
before transfection. When reaching 60%–80% confluence, 1
mg N-terminal FLAG-tagged b-catenin variant plasmids were
cotransfected with either 1 mg of APC-, AXIN-, or bTrCP-
expression plasmids by using FuGENE HD. After 24 hours,
cells were washed by cold phosphate-buffered saline 2
times, and then cold 500 mL lysis buffer was added to each
well for 15 minutes. Our main lysis buffer consisted of 30
mmol/L Tris-Cl pH 7.4, 1% Triton X-100, 150 mmol/L NaCl,
5 mmol/L EDTA, and 5 mmol/L NaF. For the b-TrCP
coimmunoprecipitation experiments, we used the following
lysis buffer: 10 mmol/L HEPES pH 7.9, 100 mmol/L NaCl,
1.5 mmol/L MgCl2, 0.1% NP40. The b-TrCP/b-catenin
interaction is short lived because of the rapid turnover by
the proteasome, se we applied 2-hour proteasome inhibi-
tion using MG132 before precipitation. To all lysis steps,
Halt Protease and Phosphatase Inhibitor Cocktail (Thermo
Fisher Scientific) was added according to the manufac-
turer’s instructions. Cells were collected by scraping, and
lysate was cleared at 4C by centrifugation at 11,000g for
15 minutes. From the cleared lysate, 10% was taken as
input control, to which the same volume of 2 Laemmli/
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dithiothreitol (DTT) was directly added, followed by heating
for 5 minutes at 95C. To the remainder of the supernatant,
we added 10 mL prewashed ANTI-FLAG M2 Affinity Gel
(Sigma-Aldrich), followed by incubation at 4C for 2 hours.
Next, FLAG-beads were centrifuged and washed with lysis
buffer for 3 times. Finally, the pellet was lysed in 50 mL 2
Laemmli sample buffer with 0.1 mol/L DTT and heated.
For the IP experiments using knock-in cell lines, cells
were seeded in 15-cm round culture plates. When nearly
confluent, cells were washed by cold phosphate-buffered
saline 2 times, and then 1.5–2 mL cold lysis buffer with
protease/phosphatase inhibitors was added to each well for
15–30 minutes. Cells were collected by scraping, and lysate
was cleared at 4C by centrifugation at 11,000g for 15 mi-
nutes. From the cleared lysate, 5%–10% was taken as input
control, to which the same volume of 2 Laemmli/DTT was
directly added, followed by heating for 5 minutes at 70C.
To the cleared lysates, 5 mL of the antibodies detecting APC
or b-catenin was added (Supplementary Table 9). In addi-
tion, APC was immunoprecipitated using 20 mL of the AFPN
antibody.4 After 2 hours of incubation at 4C, 25 mL of
Protein A/G magnetic beads (Pierce, Thermo Fisher Scien-
tific) were added and incubated for an additional 2 hours.
IPs were washed 3–4 times with lysis buffer and finally
lysed in 80 mL 2 Laemmli sample buffer with 0.1 mol/L
DTT, and heated at 70C for 5 minutes. For detecting the
Supplementary References
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b-catenin/TCF7L2 interaction, we used the following buffer:
30 mmol/L Tris-Cl pH 7.4, 0.1% Triton X-100, 150 mmol/L
NaCl, 5 mmol/L EDTA, and 5 mmol/L NaF. For detecting the
APC/b-catenin interaction we used 25 mmol/L Tris-Cl pH
7.4, 1% NP-40, 150 mmol/L NaCl, 1 mmol/L EDTA, and 5%
glycerol. Alternatively, this buffer was used: 30 mmol/L
Tris-Cl pH 7.4, 1% Triton X-100, 300 mmol/L NaCl, 5 mmol/
L EDTA, and 5 mmol/L NaF.
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Supplementary Figure 1. H&E stainings of representative HCC foci induced after hydrodynamic transfections at 4 different
magnifications. Original magnifications are shown.
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Supplementary Figure 2. All b-catenin/c-Met–induced foci are positive for the hepatocyte marker HNF4a but negative for the
biliary marker CK19. Original magnifications are shown.
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Supplementary Figure 3. Half-life determination of b-catenin mutants. (A) Indicated FLAG-tagged b-catenin variants were
cotransfected with pEGFP-C1 into HEK293 cells, followed by cycloheximide (CHX) treatment to block new protein synthesis
for the indicated times. Next, quantitative fluorescent Western blotting was performed with the highly stable GFP protein for
transfection normalization. (B) Values obtained for the 0-hour time point were arbitrarily set to 1. Normalized values for other
time points were plotted. Linear regression was performed to estimate the half-life for each variant, which is depicted on the
right. Experiment was performed at least 3 times for each variant producing similar trends in each experiment. EX3-del, exon 3
deletion.














































































































































































Supplementary Figure 4. AXIN2 RNA expression in b-catenin S37F and K335I knock-in clones. The top panels show the
AXIN2 expression levels determined by qRT-PCR (mean ± standard deviation, n ¼ 5) for all analyzed clones. The bottom
panels show the results for K335I knock-in clones only. All expression levels are depicted relative to the housekeeping gene
GAPDH. Data are presented as mean ± standard deviation. **P < .01; ***P < .001; ****P < .0001. CTR, control.
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Supplementary Figure 5. K335 and N387 directly interact with APC, TCF/LEF, and E-cadherin. (A) Sketch representation of b-
catenin in gray with its 12 armadillo repeats numbered. Bound APC (blue; 1TH1.pdb), TCF (yellow; 1G3J.pdb), E-cadherin
(green; 1I7W.pdb) and AXIN (red; 1QZ7.pdb) share binding sites in the b-catenin groove and are shown as tube representation.
(B–E) Details of the complexes depicted with b-catenin as a sketch and bound ligands as stick representation with carbons in
the same color code as in panel A, oxygen atoms in red, nitrogen atoms in dark blue, phosphorus in orange. (B) K335 from b-
catenin forms 2 ionic interactions and 3 hydrogen bonds (dashed lines) with phosphorylated serine residues and backbone
atoms of APC. (C) K335 from b-catenin forms 1 ionic bond and 2 hydrogen bonds (dashed lines) with the sidechain and
backbone of D40 in TCF. (D) K335 from b-catenin forms 1 ionic bond with phosphorylated S692 and a hydrogen bond (dashed
line) with the backbone of E-cadherin. (E) N387 from b-catenin forms 2 hydrogen bonds (dashed lines) with backbone atoms of
T1493 in APC.
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Supplementary Figure 6. Details of TCF and E-cadherin binding to b-catenin. (A) N387 from b-catenin forms 2 hydrogen
bonds with backbone groups of D23 in TCF. Hydrogen bonds are indicated with dashes. (B) N387 from b-catenin forms 2
hydrogen bonds with backbone groups of Y681 in E-cadherin. (C) TCF is bound to b-catenin via a 4-residue ion-pair network
(E334-R376-D40-K335). The presence of the hydrophobic V44 sidechain in TCF prevents polar interactions with surrounding
residues in b-catenin. (D) E-cadherin is bound to b-catenin via a different 4-residue ion-pair network (K292-Y333-pS692-K335).
Formation of ionic interactions to connect the 2 isolated networks is impossible because residue 688 in E-cadherin is an
alanine rather than a (phosphorylated) serine. (E) The sidechain of D23 in TCF is too short to form energetically favorable
interactions with W383 in b-catenin. (F) The aromatic sidechain of E-cadherin Y681 interacts with the double ring of W383 in b-
catenin via van der Waals interactions (indicated with curved lines).
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Supplementary Table 5.List of Primary Antibodies Used for Immunohistochemistry
Antibody Catalog number Company Species Dilution
b-catenin BD 610153 BD Biosciences (Franklin Lakes, NJ) Mouse 1:200
Glutamine synthetase BD 610518 BD Biosciences Mouse 1:500
Myc-tag Vli01 Maine Medical Center Research Institute (Portland, ME) Rabbit 1:150
Ki-67 MA5-14520 Thermo Fisher Scientific Rabbit 1:150
HNF4a ab181604 Abcam Rabbit 1:2000
CK19 ab133496 Abcam Rabbit 1:500
Supplementary Table 6.List of Primer Pairs Used in qRT-PCR Analysis
Gene name Forward Reverse








Supplementary Table 7.List of Antibodies Used for Western Blotting
Antibody Catalog number Company Species Dilution
FLAG F3165 Sigma-Aldrich Mouse 1:1000
pb-catenin (S33/37) #2009 Cell Signaling Technology Rabbit 1:1000
pb-catenin (S33/37/T41) #9561 Cell Signaling Technology Rabbit 1:1000
pb-catenin (T41/S45) #9565 Cell Signaling Technology Rabbit 1:1000
pb-catenin (S45) #9564 Cell Signaling Technology Rabbit 1:1000
TCF7L2 #05-511 Merck (Kenilworth, NJ) Mouse 1:1000
E-cadherin #3195 Cell Signaling Technology Rabbit 1:1000
Myc-tag Ab9106 Abcam Rabbit 1:1000
GFP A-11122 Thermo Fisher Scientific Rabbit 1:1000
APC MABC202 (FE9) Sigma-Aldrich Mouse
NOTE. Antibody specificities of phospho-specific b-catenin antibodies as provided by Cell Signaling Technology are as fol-
lows: p-bcat Ser33/37 recognizes b-catenin when phosphorylated at Ser33 or Ser37, or both; p-bcat Ser33/37/Thr41 rec-
ognizes any phosphorylation at Ser33/37/Thr41 except for pSer33 alone; p-bcat Thr41/Ser45 recognizes pThr41 or pSer45, or
both.
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Supplementary Table 8.sgRNA and ssODN Sequences
Used to Introduce the S37F and
















NOTE. The lowercase nucleotides are silent mutations in the
ssODNs that will alter the guide RNA recognition sequence to
prevent recutting. Underlined and bold A introduces the S37F
and K335I mutation.
Supplementary Table 9.List of Antibodies Used for
Immunoprecipitation
Antibody Catalog Number Company Species
b-catenin #8480 Cell Signaling Technology Rabbit
APC #2504 Cell Signaling Technology Rabbit
IgG #2729 Cell Signaling Technology Rabbit
APC AFPN Homemade4 Rabbit
IgG, immunoglobulin G.
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